HealthcareServices

Rare Disease Genetic Testing Market Size and Growth Forecast for Businesses 2025–2029

November 20, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Are The Current (2025) And Forecast (2029) Sizes Of The Rare Disease Genetic Testing Market?

The rare disease genetic testing market size has seen significant expansion in recent years. It is forecast to grow from $1.03 billion in 2024 to $1.17 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 13.6%. Factors contributing to its historical growth include growing awareness regarding rare genetic disorders, an increasing need for early and precise diagnosis, a surge in government funding for rare disease research, improved accessibility of genetic testing services, greater investments in precision medicine, and a rising prevalence of rare genetic conditions.

The rare disease genetic testing market is anticipated to experience swift expansion over the coming years. Projections indicate its value will reach $1.93 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 13.3%. This projected growth is driven by several factors, including the increasing integration of next-generation sequencing, a heightened emphasis on personalized medical approaches, increasing financial commitments to genetic research, the expansion of healthcare infrastructure in developing economies, a surge in diagnostic procedures, an uptick in hereditary cancer screenings, and the growing need for non-invasive diagnostic alternatives. Key developments expected during this period involve enhancements in genome editing technologies, sophisticated bioinformatics tools for analyzing genetic data, advancements in multi-gene panel testing, progress in portable genetic testing devices, and novel approaches to sample collection.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27404&type=smp

What Are The Main Drivers Boosting The Rare Disease Genetic Testing Industry’s Expansion?

The anticipated expansion of the rare disease genetic testing market is fueled by the rising prevalence of genetic disorders. Genetic disorders are defined as health conditions resulting from anomalies in an individual’s deoxyribonucleic acid, which can be passed down from parents or occur as novel mutations. The increase in these disorders is attributed to elevated parental age, given that older parents face a greater likelihood of transmitting genetic mutations to their offspring. Rare disease genetic testing aids in diagnosing genetic disorders through the identification of specific mutations, facilitating precise and early discovery. This testing also supports individualized treatment plans, thereby improving patient care and boosting long-term health results. As an illustration, data from May 2024, released by the National Health Service, a UK government body, indicates that 17,000 individuals are affected by sickle cell disease, an inherited genetic blood condition, with approximately 250 new diagnoses occurring annually. Consequently, the growing incidence of genetic disorders is a key impetus for the expansion of the rare disease genetic testing market.

What Are The Key Segments In The Rare Disease Genetic Testing Market?

The rare disease genetic testing market covered in this report is segmented

1) By Disease Type: Immunological Disorders, Cardiovascular Disorders, Neurological Disease, Endocrine And Metabolism Disorders Diseases, Hematological Diseases, Dermatological Disease, Other Disease Types

2) By Technology: Next-Generation Sequencing, Sanger Sequencing, Polymerase Chain Reaction Based Testing, Array Based Testing, Fluorescence In Situ Hybridization, Other Technologies

3) By Specialty: Molecular Genetic Tests, Chromosomal Genetic Tests, Biochemical Genetic Tests

4) By End-User: Hospitals And Clinics, Research Laboratories And Contract Research Organizations, Diagnostic Laboratories, Other End Users

Subsegments:

1) By Immunological Disorders: Autoimmune Disorders, Allergic Conditions, Primary Immunodeficiency Disorders, Inflammatory Disorders

2) By Cardiovascular Disorders: Congenital Heart Defects, Cardiomyopathies, Aortic Aneurysms, Pulmonary Hypertension

3) By Neurological Disease: Neurodegenerative Disorders, Neuromuscular Disorders, Epileptic Syndromes, Movement Disorders

4) By Endocrine And Metabolism Disorders Diseases: Inherited Metabolic Disorders, Thyroid Disorders, Adrenal Disorders, Diabetes Related Genetic Conditions

5) By Hematological Diseases: Hemophilia, Thalassemia, Sickle Cell Disease, Clotting Disorders

6) By Dermatological Disease: Genetic Skin Disorders, Connective Tissue Disorders, Pigmentary Disorders, Keratinization Disorders

7) By Other Disease Types: Skeletal Dysplasia, Renal Genetic Disorders, Ophthalmic Genetic Conditions, Gastrointestinal Genetic Conditions

What Trends Are Expected To Drive The Rare Disease Genetic Testing Market?

Leading companies in the rare disease genetic testing market are directing their efforts towards creating technologically sophisticated solutions, such as digital genomics platforms, to improve the speed, precision, and scalability of diagnosing rare diseases. Digital genomics platforms are advanced software systems that consolidate genomic data analysis, interpretation, and reporting to simplify and expedite genetic testing and diagnosis. For instance, in March 2025, Strand Life Sciences Private Limited, an India-based computer software company, introduced the StrandOmics Portal, a digital platform designed to enhance the efficiency and accuracy of rare disease diagnosis. This portal offers clinicians comprehensive insights into genetic variants, enabling more rapid and exact diagnoses. It also supports advanced variant interpretation, including prenatal diagnostics, and facilitates independent reviews of genetic data. This launch demonstrates a strong commitment to progressing precision medicine and equipping healthcare professionals with effective instruments to improve patient outcomes.

Which Leading Players Are Enhancing Their Rare Disease Genetic Testing Market Presence Worldwide?

Major companies operating in the rare disease genetic testing market are Thermo Fisher Scientific Inc., Quest Diagnostics Inc., Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., QIAGEN N.V., Natera Inc., OPKO Health Inc., Myriad Genetics Inc., Fulgent Genetics Inc., BioReference Laboratories Inc., Invitae Corporation, Ambry Genetics Corporation, Centogene N.V., Baylor Genetics Company, PreventionGenetics, Blueprint Genetics Oy, Realm IDX Inc., Artemis DNA Inc., BGI Genomics Co. Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/rare-disease-genetic-testing-global-market-report

What Are The Regional Market Dynamics Impacting The Rare Disease Genetic Testing Industry?

North America was the largest region in the rare disease genetic testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease genetic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Rare Disease Genetic Testing Market Report:

https://www.thebusinessresearchcompany.com/customise?id=27404&type=smp

Browse Through More Reports Similar to the Global Rare Disease Genetic Testing Market 2025, By The Business Research Company

Data Wrangling Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/data-wrangling-global-market-report

Alternative Data Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/alternative-data-global-market-report

Data Catalog Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/data-catalog-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795